CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia
Ofrat Beyar‐Katz(Rambam Health Care Campus), Yair Herishanu(Tel Aviv University), Tsila Zuckerman(Johannes Gutenberg University Mainz), Massimo Gentile(Azienda Ospedaliera di Cosenza), Sigal Grisariu(Hebrew University of Jerusalem), Avichai Shimoni, Ronit Marcus(Sheba Medical Center), Tamar Tadmor(Bnai Zion Medical Center), Giulia Gabrielli(Hospital of the University of Pennsylvania), Batia Avni(Hadassah Medical Center), Lydia Scarfò(IRCCS Ospedale San Raffaele), Roni Shouval(Memorial Sloan Kettering Cancer Center), Guido Ghilardi(Hospital of the University of Pennsylvania), Andrea Visentin(University of Padua), Κώστας Σταματόπουλος(Centre for Research and Technology Hellas), Luca Paruzzo(Hospital of the University of Pennsylvania), Noga Shem‐Tov(Tel Aviv University), Riva Fineman(Rambam Health Care Campus), Ohad Benjamini(Sheba Medical Center), Ron Ram(Tel Aviv University), Odelia Amit(Tel Aviv University), Arnon Nagler(Sheba Medical Center), Abraham Avigdor(Sheba Medical Center), Thomas Chatzikonstantinou(G. Papanikolaou General Hospital), Ronit Leiba(Rambam Health Care Campus), Núria Martínez‐Cibrián(Hospital Clínic de Barcelona), Eva Minga(Centre for Research and Technology Hellas), Elisabeth Vandenberghe(Trinity College Dublin), Stephen J. Schuster(Hospital of the University of Pennsylvania), Ronit Yerushalmi(University of Colorado Boulder), Paolo Ghia(Vita-Salute San Raffaele University), Marco Ruella(Parker Institute for Cancer Immunotherapy), Ivetta Danylesko(Sheba Medical Center), Julio Delgado(Hospital Clínic de Barcelona), Valentin Ortiz-Maldonado(Hospital Clínic de Barcelona)
Cited by 4
Related Papers
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k